International Journal of Surgery Case Reports · Nov 19, 2026

Pilonidal disease symptoms temporally associated with glucagon-like peptide-1 receptor agonist therapy – a case report

By Jo S, Abrajano C, Chiu B

Introduction and importance: Pilonidal disease (PD) is a chronic inflammatory condition associated with secondary infection, most commonly with anaerobic, gut-derived bacteria belonging to the Bacteroidota phylum. Glucagon-like peptide-1 (GLP-1) receptor agonists have been found to alter the gut microbiome and increase the abundance of Bacteroidota . Patients with PD often have other comorbidities, such as obesity, which is now commonly treated with GLP-1 receptor agonists. In this report, we describe three patients with new-onset or recurrent PD symptoms after taking GLP-1 receptor agonists. Case presentation: Three patients with PD presented to our Pilonidal Care Clinic with either new-onset gluteal cleft symptoms or recurrent PD. All three had recently started treatment with GLP-1 receptor agonists. Two patients underwent a Gips procedure, and one required incision and drainage. Wound cultures from two patients grew Prevotella , belonging to the phylum Bacteroidota . All wounds healed successfully after intervention, and all patients resumed taking GLP-1 receptor agonists. Clinical discussion: Pilonidal sinuses are commonly infected with Bacteroidota , and initiating GLP-1 receptor agonists can increase the intestinal population of Bacteroidota. A potential temporal relationship between the initiation of GLP-1 receptor agonists and the development of PD symptoms may exist. Patients with PD who are on GLP-1 receptor agonists should be carefully observed. Conclusion: There may be a temporal association between taking GLP-1 receptor agonists and the development of PD symptoms. Recognition of this possibility may lead to early recognition of pilonidal symptoms in patients and to hypothesis generation for future investigation.

doi.org/10.1097/rc9.0000000000001318Populations

AgingResearch.News